Hope and Exploitation in Commercial Provision of Assisted Reproductive Technologies
Innovation is a key driver of care provision in assisted reproductive technologies (ART). ART providers offer a range of add-on interventions, aiming to augment standard in vitro fertilization protocols and improve the chances of a live birth. Particularly in the context of commercial provision, an...
| Главные авторы: | ; ; ; |
|---|---|
| Формат: | Электронный ресурс Статья |
| Язык: | Английский |
| Проверить наличие: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Опубликовано: |
2023
|
| В: |
The Hastings Center report
Год: 2023, Том: 53, Выпуск: 5, Страницы: 30-41 |
| Другие ключевые слова: | B
Physician-patient relationship
B Bioethics B Hope B assisted reproductive technologies B Exploitation |
| Online-ссылка: |
Volltext (kostenfrei) Volltext (kostenfrei) |
| Итог: | Innovation is a key driver of care provision in assisted reproductive technologies (ART). ART providers offer a range of add-on interventions, aiming to augment standard in vitro fertilization protocols and improve the chances of a live birth. Particularly in the context of commercial provision, an ever-increasing array of add-ons are marketed to ART patients, even when evidence to support them is equivocal. A defining feature of ART is hope—hope that a cycle will lead to a baby or that another test or intervention will make a difference. Yet such hope also leaves ART patients vulnerable in a variety of ways. This article argues that previous attempts to safeguard ART patients have neglected how the use of add-ons in commercial ART can exploit patients’ hopes. Commercial providers of ART should provide add-ons only free of charge, under a suitable research protocol. |
|---|---|
| ISSN: | 1552-146X |
| Второстепенные работы: | Enthalten in: Hastings Center, The Hastings Center report
|
| Persistent identifiers: | DOI: 10.1002/hast.1513 |
